Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGONIVO: Regorafenib and Nivolumab in Advanced Solid Tumors
NCT03406871Phase 1Completed
- Start
- Jan 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of regorafenib and nivolumab in solid tumor, gastric cancer (GC), colorectal cancer (CRC) and 1 more (4 arms). Primary endpoint: Dose Limiting Toxicity at 4 weeks. Started Jan 2018; status: completed.
02
Drugs
regorafenibnivolumab
03
Conditions
solid tumorgastric cancer (GC)colorectal cancer (CRC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03406871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03406871.